Preparation and Applications of Dextran-Derived Products in Biotechnology and Related Areas

Effect of the Chemical Modification of Dextran on the Degradation by Dextranase

Dextran was modified using three different methods: a) partial periodate oxidation and subsequent reduction of the aldehyde groups, b) suc cinoylation and c) chloroformate activation with subsequent reaction with 2- hydroxypropylamine, ethylenediamine and tris(2-aminoethyl)amine. Degrada tion of these dextran derivatives by dextranases was investigated. It was observed that the rate of degradation decreased with increasing degree of chemical modification of the parent polysaccharide. The nature of modification had no significant influence on the rate of degradation.

Synthesis of Glycosylated Dextrans

Dextran fractions with a narrow molecular weight distribution were modified using the 4-nitrophenyl chloroformate activation method. The activated polymers were subsequently reacted with a small amount of L- tyrosinamide and a number of selected peracetylated ω-amino glycosides of D- mannose, D-galactose, L-fucose and L-rhamnose and including some cluster de rivatives. All monosaccharides were linked to the polymer chain via a carbon C-6 spacer.

The number of L-tyrosinamide units introduced could be accurately deter mined by UV absorption spectroscopy. On the other hand, the degree of substi tution by a glycoside ligand was calculated from 1H NMR data.

Dextran-protamine polycation: an efficient nonviral and haemocompatible gene delivery system

Despite the remarkable progress in the field of gene therapy with viral vectors, nonviral vectors have attracted great interests due to their unique properties. Imparting desired characteristics to nonviral gene delivery systems requires the development of cationic polymers. The purpose of this work was to design a cationic derivative (Dex-P) of dextran using protamine in order to assert target specific cellular binding. Our objective was to elucidate the potential use of Dex-P as a haemocompatible, nontoxic and efficient nonviral candidate for gene therapy. Nanoplexes were prepared with calf thymus DNA and Dex-P. Derivatization was confirmed by FTIR, gel permeation chromatography and TNBS assay. Dynamic light scattering and TEM studies determined the size and morphology of the nanoplex. The buffering behaviour was assessed by acid base titration. Complexation stability was evaluated using agarose gel electrophoresis and EtBr displacement assay. The protection of ctDNA from nuclear digestion and the effect of plasma components towards stability of the nanoplexes were also analyzed. Various haemocompatible studies were performed to check haemolysis, aggregation, clotting time, and complement activation. Transfection and cytotoxicity experiments were performed in vitro. The nanosize, spherical shape and stability of nanoplexes were affirmed. Various experiments conducted confirmed Dex-P to be nontoxic and haemocompatible. Transfection experiments revealed the capability of Dex-P to facilitate high gene expression and cellular uptake in HepG2 cells. With the improved physicochemical, biological and transfection properties, Dex-P seems to be a promising gene delivery system.